Israel’s Kamada (reported here previously) has signed a deal to supply Israel’s Health ministry with its plasma-based hyperimmune immunoglobulin (IgG) product. The product treats COVID-19 patients with pneumonia and is currently in Phase 1 & 2 trials in Israel.

https://nocamels.com/2020/10/kamada-deal-supply-israel-health-ministry-covid-19-antibody/